-- but more than half of these women switched back to bisexual or unla... By year 10 most of the women were involved in long-term (i.e... Women's definitions of lesbianism appeared to permit more fle... This provides further support for the notion that female sexuality is......
Date:1/15/2008
-- but more than half of these women switched back to bisexual or unlabeled by the end.
- By year 10, most of the women were involved in long-term (i.e., more than a year in length) monogamous relationships -- 70 percent of the self-identified lesbians, 89 percent of the bisexuals, 85 percent of the unlabeled women and 67 percent of those who were then calling themselves heterosexual.
- Women's definitions of lesbianism appeared to permit more flexibility in behavior than their definitions of heterosexuality. For example, of the women who identified as lesbian in the last round of interviews, 15 percent reported having sexual contact with a man during the prior two years. In contrast, none of the women who settled on a heterosexual label at that point reported having sexual contact with a woman within the previous two years.
"This provides further support for the notion that female sexuality is relatively fluid and that the distinction between lesbian and bisexual women is not a rigid one," Diamond wrote.
'/>"/>
Page: 1 2 Related medicine news :1.
Seabrook House Opens Transitional Living Facility: Seabrook West2.
Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)3.
Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma4.
Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial5.
Cytopia Commences Phase II Cancer Drug Study6.
QRxPharma Initiates Second Phase III Clinical Trial for its Dual Opioid Pain Therapy7.
PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study8.
Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma9.
Early Phase II results show bosutinib safe, effective for CML10.
CuraGen and TopoTarget Report Belinostat Results Presented at ASH and Provide Regulatory Update Following End-of-Phase II Meeting with FDA11.
VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial